Medivir: MIV-701 Preclinical Efficacy Data Presented.STOCKHOLM, Sweden -- Regulatory News: Medivir (STO:MVIRB) has presented efficacy data for MIV-701 in a preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. osteoporosis model at the ongoing conference of the American Society for Bone and Mineral Research in Hawaii. The results demonstrate that administration of MIV-701 in this preclinical disease model significantly reduces osteoclast osteoclast /os·teo·clast/ (os´te-o-klast?) 1. a large multinuclear cell associated with absorption and removal of bone. 2. an instrument used for osteoclasis. cell activity via inhibition of the enzyme cathepsin K Cathepsin K, which is defined by its high specificity for kinins, is involved in bone resorption. Cathepsin K's ability to catabolize elastin, collagen, and gelatin allow it to break down bone and cartilage. . An increase in osteoclast activity leads to bone degradation and consequently osteoporosis. The activity of MIV-701 is reversible (i.e. ceases when administration no longer is continued), which is a big therapeutic advantage over other treatment regimes such as the bisphosphonates which are the conventional form of treatment today. MIV-701 is currently in phase I clinical trials Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I (where the safety, tolerability and pharmacokinetics of the drug compound is studied in healthy volunteers). The first studies (phase Ia) are now completed and the phase Ib is underway. This study includes an arm with post-menopausal women (a population often afflicted af·flict tr.v. af·flict·ed, af·flict·ing, af·flicts To inflict grievous physical or mental suffering on. [Middle English afflighten, from afflight, with osteoporosis) in which the efficacy of MIV-701 on a biomarker biomarker /bio·mark·er/ (bi´o-mahr?ker) 1. a biological molecule used as a marker for a substance or process of interest. 2. tumor marker. bi·o·mark·er n. 1. for osteoporosis will be studied. The phase I clinical trials are expected to be completed and ready for evaluation before the end of the year, and the results will be communicated thereafter. For more information on Medivir, please see the company website: www.medivir.se This information was brought to you by Cision http://newsroom.cision.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion